ASSOCIATION BETWEEN CYP2C19 GENE POLYMORPHISMS AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

This study aims to investigate CYP2C19 gene polymorphisms and the association between with cardiovascular risk factors major adverse events (MACE) in patients acute myocardial infarction (AMI). A prospective cross-sectional analysis involved 86 AMI enrolled assessed MACE evaluated after three months of treatment. CYP2C19*1*1 genotype accounted for highest prevalence at 54.7%, which means normal metabolizers phenotype was highest. The circumflex artery stenting, medical history taking clopidogrel, percutaneous coronary intervention (PCI), hypertension polymorphism significantly higher than those without polymorphism, 35.9 vs. 10.6, 46.2 14.9,10.3 vs., 9.49 74.5, respectively (p<0.05). In polymorphisms, using a combination clopidogrel aspirin regimen had 13.6% mortality, while ticagrelor 0% (p>0.05). relationship treatment not associated. is associated hypertension, PCI, stenting injury. established who require testing this when suffering from have medicine adaptation method. Keywords: Polymorphism, , Acute Myocardial Infarction, Major Adverse Cardiovascular Events, Percutaneous Coronary Intervention DOI： https://doi.org/10.35741/issn.0258-2724.58.3.11